期刊文献+

HCV患者年龄、抗体和HCV RNA与血清分型的关系

Study of the Relationship Between the Age of Patients with HCV,Antibodies to HCV RNA and the Viral Serotypes
下载PDF
导出
摘要 目的采用建立的丙型肝炎病毒(HCV)血清分型技术,探讨HCV患者年龄、抗体(S/CO)和HCV RNA与血清分型的关系。方法收集HCV慢性感染患者血清200例,定量检测HCV RNA、抗-HCV,同时进行血清分型,并进行统计分析。结果 200例慢性丙肝患者的血清抗-HCV抗体均为阳性,S/CO〉3.5,HCV RNA滴度在1.12×103~9.29×107 copies/ml。其中血清1型102例,2型58例,混合型2例,分型率为81.00%。采用Student t检验分析年龄、抗体S/CO、HCV RNA与分型之间的关系,t值分别为1.842 9,0.446 7,1.778 2,P均〉0.05,无统计学意义。结论 HCV患者年龄、抗体(S/CO)和HCV RNA滴度对血清分型结果没有影响。 Objective To establish the hepatitis C virus(HCV)serotyping techniques to explore the relationship between the age of patients infected with HCV,antibodies(S/CO),HCV RNA and serotypes.Methods Two hundred cases of serum samples of HCV chronic infection were collected,including 101 cases of male,99 cases of female with the average age of 44 years.Quantitative detection of HCV RNA,anti-HCV test,and serotyping were used for the investigation,and the Student t test was used for statistical analysis.Results Two hundred cases of anti-HCV antibodies of patients with chronic hepatitis C were positive(S/CO〉3.5),HCV RNA titers were from 1.12×103 to 9.29×107 copies/ml.In 200 serum samples of chronic hepatitis C patients,102 cases showed the type 1,58 cases exhibited type 2,and a mixed genotype was noted in 2cases.The sensitivity reached up to 81.00%.In comparison of the factors between age,antibody S/CO,HCV RNA,and serotypes,no statistical significance was seen(t values were 1.842 9,0.446 7,1.778 2,P〉0.05.Conclusions There is no obvious association of the age of patients with HCV,antibody titers(S/CO),and HCV RNA with HCV serotypes.
出处 《临床输血与检验》 CAS 2015年第2期100-102,共3页 Journal of Clinical Transfusion and Laboratory Medicine
基金 "十二五"重大传染病专项研究课题(No.2012ZX10002003-004-009)资助
关键词 丙型肝炎病毒 血清型 HCV RNA 抗体(S/CO) Hepatitis C virus Serotyping HCV RNA Antibody(S/CO)
  • 引文网络
  • 相关文献

参考文献9

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2徐皖苏,王磊,耿大影,张立新,王丽,秦晓华.Murex丙型肝炎病毒血清分型试剂应用及其评价[J].国外医学(临床生物化学与检验学分册),2005,26(7):473-473. 被引量:5
  • 3De Cock L, Vranckx R. Serotyping and genotyping of hepatitis C Virus in Belgium[J]. Infection, 2003, 31 (2) :92-97.
  • 4Elsawy EM ,Sobh MA ,EL-Chenawi FA ,et al. Serotyp- ing of hepatitis C virus in hemodialysis patients:com- parison with a standardizedgenotyping assay[J]. Diagn Microbiol Infec Dis, 2005,51 (2) : 91-94.
  • 5Fabrizi F,Martin P,Quan S,et al. Serotyping Strip Im- munoblot Assay for Assessing Hepatitis C Virus Strains in Dialysis Patients [J]. Am J Kidney Dis, 2000,35 (5) : 832-838.
  • 6Gish RG, Qian KP, Quan S,et al. Concordance be- tween hepatitis C virus serotyping assays i-J]. J Viral Hepat, 1997,4(6) :421-422.
  • 7Kobayashi M ,Chayama K ,Arase Y. Enzyme-linked im- munosorhent assay to detect heapatitis C virus serolog- ical groups 1 to 6[J]. J Gastroenterol, 1999, 34(4): 505-509.
  • 8唐小平,袁小珍,唐漾波,吴婉芬,刘国莲.丙型肝炎病毒血清抗体分型研究[J].中华传染病杂志,1997,15(4):194-196. 被引量:9
  • 9Gault E, Soussan P, Morice Y,et al. Evaluation of a New Serotyping Assay for Detection of Anti--Hepatitis C Virus Type-Specific Antibodies in Serum Samples [J]. J Clin Microbiol, 2003,41 (5) .-2084-2087.

二级参考文献21

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献744

相关作者

;
使用帮助 返回顶部